deferasirox has been researched along with 3-(trimethoxysilyl)propylamine in 1 studies
| Studies (deferasirox) | Trials (deferasirox) | Recent Studies (post-2010) (deferasirox) | Studies (3-(trimethoxysilyl)propylamine) | Trials (3-(trimethoxysilyl)propylamine) | Recent Studies (post-2010) (3-(trimethoxysilyl)propylamine) |
|---|---|---|---|---|---|
| 832 | 136 | 572 | 97 | 0 | 58 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alibolandi, M; Babaei, M; Moghadam, SMM; Mosafer, J; Ramezani, M; Saljooghi, AS | 1 |
1 other study(ies) available for deferasirox and 3-(trimethoxysilyl)propylamine
| Article | Year |
|---|---|
Fabrication of deferasirox-decorated aptamer-targeted superparamagnetic iron oxide nanoparticles (SPION) as a therapeutic and magnetic resonance imaging agent in cancer therapy.
Topics: Animals; Antineoplastic Agents; Aptamers, Nucleotide; Cell Line, Tumor; CHO Cells; Contrast Media; Cricetulus; Deferasirox; Female; Humans; Immobilized Nucleic Acids; Iron Chelating Agents; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mice, Inbred BALB C; Neoplasms; Precision Medicine; Propylamines; Silanes | 2021 |